Kazumasa Shinozuka Selected Research

cordycepin

1/2015	Anticancer and antimetastatic effects of cordycepin, an active component of Cordyceps sinensis.
11/2013	Inhibitory effect of cordycepin on experimental hepatic metastasis of B16-F0 mouse melanoma cells.
10/2009	Inhibitory effect of cordycepin on hematogenic metastasis of B16-F1 mouse melanoma cells accelerated by adenosine-5'-diphosphate.
6/2008	Cordycepin (3'-deoxyadenosine) inhibits the growth of B16-BL6 mouse melanoma cells through the stimulation of adenosine A3 receptor followed by glycogen synthase kinase-3beta activation and cyclin D1 suppression.
1/2006	Antitumor effect of cordycepin (3'-deoxyadenosine) on mouse melanoma and lung carcinoma cells involves adenosine A3 receptor stimulation.
1/2005	Effect of cordycepin (3'-deoxyadenosine) on hematogenic lung metastatic model mice.
12/2004	Antitumour activity of cordycepin in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kazumasa Shinozuka Research Topics

Disease

18	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021 - 12/2004
11	Neoplasms (Cancer) 01/2015 - 01/2003
10	Melanoma (Melanoma, Malignant) 01/2019 - 02/2003
5	Carcinoma (Carcinomatosis) 01/2019 - 01/2006
4	Neoplasm Metastasis (Metastasis) 11/2013 - 01/2003
3	Overactive Urinary Bladder (Overactive Bladder) 12/2021 - 01/2019
3	Hypertension (High Blood Pressure) 09/2015 - 11/2010
3	Body Weight (Weight, Body) 07/2013 - 12/2002
3	Experimental Melanoma 12/2004 - 01/2003
2	Fatigue 01/2020 - 08/2019
2	Vascular Diseases (Vascular Disease) 04/2016 - 02/2006
2	Atherosclerosis 01/2014 - 07/2009
2	Fibrosarcoma 03/2009 - 06/2008
1	Dizziness (Lightheadedness) 02/2021
1	Headache (Headaches) 02/2021
1	Sleep Initiation and Maintenance Disorders (Insomnia) 02/2021
1	Type 2 Diabetes Mellitus (MODY) 01/2021
1	Proteinuria 01/2021
1	Diarrhea 01/2020
1	Constipation 08/2019
1	Inflammation (Inflammations) 10/2014
1	Arteriosclerosis 01/2014
1	Hyperuricemia 01/2014
1	Hemorrhage 01/2012
1	Insulin Resistance 05/2011
1	Morbid Obesity 11/2010

Drug/Important Bio-Agent (IBA)

9	Nitric Oxide (Nitrogen Monoxide)FDA Link 04/2017 - 02/2006
7	cordycepinIBA 01/2015 - 12/2004
5	PAR-2 ReceptorIBA 01/2021 - 10/2014
3	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 12/2021 - 01/2020
3	SmokeIBA 01/2019 - 07/2009
3	Ginkgo biloba extract (Rokan)IBA 01/2012 - 04/2002
3	Protein Kinase CIBA 05/2008 - 02/2003
2	EnzymesIBA 01/2021 - 12/2002
2	Nicotine FDA Link 01/2019 - 07/2009
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2019 - 01/2010
2	SaltsIBA 09/2015 - 01/2007
2	ApolipoproteinsIBA 01/2014 - 07/2009
2	CalciumIBA 02/2013 - 06/2008
2	Telmisartan (Micardis)FDA Link 02/2013 - 05/2011
2	Glucose (Dextrose)FDA LinkGeneric 05/2011 - 11/2010
2	Adenosine Triphosphate (ATP)IBA 03/2009 - 06/2008
2	Adenosine A3 ReceptorIBA 06/2008 - 01/2006
2	midostaurinIBA 03/2003 - 02/2003
1	Adrenergic Receptors (Adrenergic Receptor)IBA 12/2021
1	N- (4- ((5- (hydroxy(phenyl)methyl)pyrrolidin- 2- yl)methyl)phenyl)- 4- oxo- 4,6,7,8- tetrahydropyrrolo(1,2- a)pyrimidine- 6- carboxamideIBA 12/2021
1	BenzodiazepinesIBA 02/2021
1	Hypnotics and Sedatives (Sedatives)IBA 02/2021
1	Muscarinic AntagonistsIBA 01/2021
1	mirabegronIBA 01/2021
1	Vasodilator Agents (Vasodilators)IBA 01/2021
1	Sodium-Glucose Transport ProteinsIBA 01/2021
1	Charcoal (Charbon)IBA 01/2020
1	Siberian ginseng rootIBA 01/2020
1	Carbachol (Carbastat)FDA Link 01/2020
1	Angiotensin II Type 1 Receptor BlockersIBA 10/2019
1	azilsartanIBA 10/2019
1	Loperamide (Imodium)FDA LinkGeneric 08/2019
1	royal jellyIBA 08/2019
1	2-butenal (crotonaldehyde)IBA 01/2019
1	Acrolein (Aqualin)IBA 01/2019
1	Carrier Proteins (Binding Protein)IBA 01/2019
1	Furaldehyde (Furfural)IBA 01/2019
1	3-buten-2-one (methyl vinyl ketone)IBA 01/2019
1	Cholinergic Antagonists (Anticholinergics)IBA 01/2019
1	ApelinIBA 12/2018
1	Cysteine (L-Cysteine)FDA Link 12/2018
1	2-furoyl-LIGRLO-amideIBA 04/2017
1	Cyclic GMPIBA 04/2017
1	SaponinsIBA 04/2016
1	AdipokinesIBA 01/2016
1	Tissue Inhibitor of Metalloproteinase-2IBA 01/2015
1	Nitric Oxide Synthase (NO Synthase)IBA 01/2015
1	Matrix Metalloproteinases (MMPs)IBA 01/2015
1	Tissue Inhibitor of MetalloproteinasesIBA 01/2015
1	Peptide Hydrolases (Proteases)FDA Link 10/2014
1	Uric Acid (Urate)IBA 01/2014
1	Apolipoproteins E (ApoE)IBA 01/2014
1	Allopurinol (Remid)FDA LinkGeneric 01/2014
1	Therapeutic UsesIBA 01/2014
1	BenzbromaroneIBA 01/2014
1	Alanine Transaminase (SGPT)IBA 11/2013
1	Nitroprusside (Sodium Nitroprusside)FDA LinkGeneric 07/2013
1	Acetylcholine (Acetylcholine Chloride)FDA Link 07/2013
1	tempolIBA 07/2013
1	Proteins (Proteins, Gene)FDA Link 02/2013
1	Warfarin (Coumadin)FDA LinkGeneric 01/2012
1	Serum AlbuminIBA 09/2011
1	CholesterolIBA 05/2011
1	Triglycerides (Triacylglycerol)IBA 05/2011
1	sesaminIBA 01/2010
1	Vinblastine (Vinblastine Sulfate)FDA Link 01/2010
1	Taurine FDA Link 01/2010
1	CurcuminIBA 01/2010
1	Capsaicin (Zostrix)FDA Link 01/2010
1	GenisteinIBA 01/2010

Therapy/Procedure

3	Therapeutics 01/2021 - 01/2019
2	Drug Therapy (Chemotherapy) 12/2021 - 01/2003
1	Oral Administration 08/2019
1	Protein-Restricted Diet (Diet, Protein Restricted) 09/2011